Report from the 2015 Annual General Meeting in Aerocrine

The Annual General Meeting (AGM) in Aerocrine AB (Nasdaq Stockholm: AERO) was
held on Tuesday, May 12, 2015, in Solna
The parent company’s and the group’s income statements and balance sheets were
adopted. It was resolved that no dividend shall be paid and that the year’s loss
shall be carried forward.

Rolf Classon, Lars Gustafsson, Dennis Kane, Michael Shalmi and Maria Strømme
were re-elected as Board members. Lennart Johansson was elected as new Board
member. Rolf Classon was re-elected as Chairman of the Board.

Fees shall be payable to Board members with an amount of SEK 250,000 to the
Chairman and SEK 125,000 to each other Board member. Compensation for committee
work shall amount to SEK 25,000 to the chairman of the Audit Committee and SEK
12,500 to each other member of the committee, and SEK 25,000 to the chairman of
the Remuneration Committee and SEK 12,500 to each other member of the committee.

The AGM resolved that the Nomination Committee shall consist of representatives
from the four largest shareholders by voting powers (grouped by owner) and the
Chairman of the Board. The composition of the Nomination Committee shall be
based on the share register maintained by Euroclear Sweden AB as per August 31
each year and be published immediately following the appointment of the
Nomination Committee, however by no later than six months prior to each Annual
General Meeting.

The guidelines for determination of salary and other remuneration to senior
management proposed by the Board were approved by the AGM.

The AGM resolved to approve the Board’s proposal to authorize the Board to
resolve – at one or several occasions and for the time period until the next
Annual General Meeting – to increase the company’s share capital by new share
issues and to issue warrants and convertible bonds, to the extent that it
corresponds to a dilution of not more than 10 percent of the number of shares
outstanding, after full exercise of the authorization. New share issues, as well
as issues of warrants and convertible bonds, may be made with or without
deviation from the shareholders’ preferential rights and with or without
provisions for contribution in kind, set-off or other conditions.

For full information on the resolutions by the AGM, see www.aerocrine.se, where
documentation relating to the AGM is available for download.

For more information please contact:

Scott Myers, Chief Executive Officer, Aerocrine AB: +1 970 368 0336 or +46 768
788 379

Marshall Woodworth, Chief Financial Officer, Aerocrine AB: +1 919 749 8748 or
+46 709 695 219

About Aerocrine

Aerocrine AB is a medical products company focused on improved management and
care of patients with inflammatory airway diseases such as Asthma. Within this
sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® and NIOX
VERO®, which enables fast and reliable point-of-care measurement of airway
inflammation. These products play a critical role in more effective diagnosis,
treatment and follow-up of patients affected with inflammatory airway diseases.
Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland
and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange
since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and
www.niox.com.

Aerocrine is required to disclose the information provided herein pursuant to
the Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 08:00am CET on May 13, 2015.